1. France Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Eurofins-Cerep S.A.

Eurofins-Cerep S.A.

ALECR.PA
Eurofins-Cerep S.A.undefined flagEuronext Paris
16,100.00
EUR
- -
- -
81.21MMarket Cap
Eurofins-Cerep S.A.
ALECR.PA
(Euronext Paris)

Recent

price

16,100.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
4,794.81
4,609.83
3,685.17
3,978.92
3,669.78
4,463.6
4,646.71
5,158.49
5,046.25
6,147.55
6,476.44
8,250.75
9,442.59
8,737
8,020.87
8,123.52
Revenue per Share
-1,071.77
-15.66
62.85
-175.01
-98.16
358.53
492.86
813.61
764.98
866.43
1,105.73
1,951.38
2,284.78
1,514.43
1,418.43
948.15
Basic EPS, GAAP
-379.06
471.05
55.71
-437.03
-700.66
-102.56
5.55
671.17
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-321.57
734.54
813.05
492.61
398.26
756.56
1,249.6
1,348.53
2,030.09
2,896.53
4,002.26
4,847.91
7,132.69
8,647.11
10,065.54
11,013.69
Book Value per Share
2,626.88
2,629.46
2,721.05
2,673.02
2,593.73
2,964.99
3,407.41
4,446.15
4,936.23
5,406.55
6,518.17
8,552.99
10,843.76
12,367.31
13,739.93
14,705.05
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
24
23
19
20
18
23
23
24
25
31
33
42
48
44
40
41
Sales/Revenue/Turnover
-12.67
4
9.4
0.02
29.32
4.38
6.96
15.54
19.17
14.12
17.78
24.27
24.61
14.63
10.96
8.75
Operating Margin (%)
2
2
1
1
- -
1
-1
- -
1
1
1
1
2
2
2
2
Depreciation Expense
-5
- -
- -
-1
- -
2
2
4
4
4
6
10
12
8
7
5
Net Income, GAAP
- -
12.37
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-22.35
-0.34
1.71
-4.4
-2.67
8.03
10.61
15.77
15.16
14.09
17.07
23.65
24.2
17.33
17.68
11.67
Profit Margin (%)
15
6
6
15
14
15
15
19
22
24
29
36
46
53
62
69
Working Capital
4
3
2
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
14
14
14
14
13
15
17
21
25
30
35
45
57
65
72
76
Total Equity
- -
3.91
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
2.45
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
8.12
-26.93
-21.94
62.11
49.13
60.71
46.43
35.17
32.06
44.1
38.14
19.19
15.16
9
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.89%
17.17%
6.61%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
15.38%
4.07%
-33.15%
Sales/Revenue/Turnover
6.72%
5.49%
1.28%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
44
2024
- -
- -
- -
- -
40
2025
- -
- -
- -
- -
41

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1,514.43
2024
- -
- -
- -
- -
1,418.43
2025
- -
- -
- -
- -
948.15

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Prostatype Genomics AB (publ) (PROGEN.ST)
Human Metabolome Technologies, Inc. (6090.T)
Akumin Inc. (AKU)
Cyclo3pss Corporation (CYPS)
ACS Global, Inc. (AMCY)
Diagnósticos da América S.A. (DASA3.SA)
Business
Eurofins-Cerep SA provides drug discovery services, including compound management, high-throughput screening, profiling, in vitro pharmacology, in vitro ADME-Tox studies, and in vivo pharmacokinetic services, to pharmaceutical, biopharmaceutical, and biotechnology companies in France and internationally. Founded in 1989 and headquartered in Celle-Lévescault, France, the company operates as a subsidiary of Eurofins Discovery Services LUX Holding SARL, following its name change from Cerep SA in June 2014. Eurofins-Cerep specializes in pre-clinical research solutions for drug development, with exports accounting for the majority of its net sales.